摘要
目的:探讨对重症肺炎合并呼吸衰竭患者进行免疫调理治疗的临床疗效。方法:53例患者随机分为治疗组和对照组,治疗组在常规抗感染、机械通气等治疗的基础上,进行免疫调理治疗(应用胸腺肽α1和乌司他丁连续7d),观察两组患者肺部感染控制窗出现时间、机械通气时间、ICU住院时间、治愈率、死亡率等指标的差别。结果:与对照组相比,治疗组的肺部感染控制窗出现时间早,机械通气时间及ICU住院时间短、治愈率高、死亡率低,差异均具有统计学意义(P<0.05)。结论:对重症肺炎合并呼吸衰竭患者进行免疫调理治疗,有利于患者肺部感染的控制,可以提高临床治愈率,降低患者的死亡率。
Objective：To investigate the effect of immunomodulatory treatment in the severe pneumonia patients with respiratory failure.Methods：53 patients were divided into two groups randomly,therapy group and control group.All groups were given routine therapy such as anti-infection and ventilation,while the therapy group was given immunomodulatory treatment with thymosin-α1 and ulinastatin at the same time for seven days.Time of pulmonary infection control window,the length of ventilation,the ICU length of stay,the recovery rate and the mortality rate were recorded.Results：After treatment,compared with the control group,time of pulmonary infection control window,the length of ventilation,the ICU length of stay and the mortality rate in therapy group decreased significantly（P〈0.05）,while the recovery rate was rised significantly （P〈0.05）.Conclusion：Immunomodulatory treatment in severe pneumonia patients with respiratory failure is beneficial to pulmonary infection control,it can improve the clinical recovery rate and decrease the mortality rate.
出处
《中国当代医药》
2010年第10期31-32,共2页
China Modern Medicine
关键词
重症肺炎
呼吸衰竭
免疫调理
Severe pneumonia
Respiratory failure
Immunomodulatory treatment
